

Focus on
Cardiac
Ablation and
AEF Prevention

ICEolate®

The CPSI Biotech ICEolate® and SCN Platform

Provides for a next generation approach to treating **Atrial Fibrillation (AF)**

Technology Overview


The ICEolate® platform is a series of specialized epicardial and endocardial cryoablation probes and catheters for use with CPSI's SCN or PSN cryoablation system for the treatment of various cardiac arrhythmias. The design and power of the system allows for delivery of this ablative dose either epicardially or endocardially in a fully beating heart, thereby eliminating the need for bypass or other form of stopping blood flow in the targeted region.

In conjunction with the SCN system, the ICEolate® disposable probe platform allows for the rapid delivery of a precise, full thickness (transmural), highly ablative thermal dose to targeted cardiac tissue in less than 2 minutes.

ICEolate® System

- ICEolate® Cryoablation Disposables
- Supports Epicardial and Endocardial Access
- Flexible, Steerable probes and catheters
- Handle control operation and displays
- Compatibility with a variety of tip configurations
 - Spot, linear, flexible, rigid, balloon
- *RapidRelease* thawing technology
- Ice formation within 5 seconds
- Transmural lesion formation in 30-60 seconds
- No-bypass or blockage of blood flow necessary

ICEolate® probes include designs to conduct Pulmonary Vein Isolation, treatment of Atrial Fibrillation (AF), atrial flutter, ventricular tachyarrhythmia and other cardiovascular disease states.



SCN System



SCN (Super-Critical Nitrogen) System

- Converts LN2 to SCN
- Self-contained device
- Dual Port supporting multi-probes if desired
- The SCN System allows for:
 - Cryogen delivery via ultrafine tubing
 - Rapid heat extraction from tissue
 - Recycling of cryogen during operation
 - Continuous delivery of ultra-cold cryogen
- Delivers superior ablation capacity



Lesion causing PR prolongation
30 sec, -168.3°C

Lesion causing transient AVB,
15 sec, -168°C

Images of the transmural lesions created by the ICEolate® Cryocatheter and the SCN System within a Beating Heart

The ICEolate® and SCN System permits effective cryoablation of cardiac tissue. The system exhibited extremely rapid lesion formation (with 15 second applications). Large lesions could be formed due to SCN rapid cooling capability and available catheter tip configurations. The ICEolate® and SCN system proved to be a POWERFUL ablation tool which shows potential for creating long, continuous linear lesions with single brief applications

Market Overview


Overall there are 4 million individuals in the US with AF (atrial fibrillation) projected to increase to 10-12 million within the next 20 years. The global market for treatment of AF is projected to reach \$4.1 billion in 2015. The US market for ablation devices (equipment and consumables) used for treatment of AF is forecasted to reach \$344 million in 2016 (approximately 250,000 ablations) based on a projected CAGR of 13.8%.

The power and versatility of the innovative **ICEolate®** platform allows for the treatment of a host of cardiac arrhythmias thereby increasing its utility and impact and setting it apart from other devices within the cardiac ablation therapy arena. Based on an initial conservative 1% market penetration 1yr post launch, CPSI anticipates generating annual revenues of ~\$4.5 MM from product sales after 3 years, ~\$22MM after 5 years and >\$70MM after 8 years from initial investment and product launch.

Intellectual Property

2 Patents Issued and Several Patents pending with the USPTO covering:

- ❖ Cryoablation system for minimally-invasive treatment of cardiac arrhythmias
- ❖ A line of surgical and catheter based ablation probes for use in cardiac arrhythmia ablation



Comparison of Time to Critical Tissue Temperature at Various Points in an Ex Vivo Porcine Tissue Model

The ICEolate® and SCN System delivers a rapid, colder, more precise cryoablative insult compared to other technologies. The power of SCN allows for the penetration of lethal temperatures across thick tissue within seconds even in high heat load (blood flow) environments.


COMPETITIVE ADVANTAGE

Performance Differentiator

- ❖ Speed, power and heat extraction capacity
- ❖ Catheter and surgical procedure compatible
- ❖ Closed loop system
- ❖ No Bypass needed
- ❖ Transmural lesion within 1 minute

Cost Differentiator

- ❖ Elimination of costly argon and nitrous oxide
- ❖ Green technology – use of nitrogen
- ❖ Single console supporting multiple approaches
- ❖ Reduced procedure time, OR time, risk and cost



Business Development and Investment Opportunity

Our mission is to rapidly translate new and innovative technologies through the concept and development phases and into the commercialization stage to bring these technologies to the market. In support of these efforts, CPSI welcomes inquires and discussions pertaining to equity investment as well as business relationships (sales, acquisition, licensing, partnering) for the ICEolate® and SCN System.

Caution: Investigational Devices Limited by Federal Law to Investigational Use Only